Trial Profile
A 2-Part Ascending Multiple Oral Dose, Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Ulotaront (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sumitomo Pharma
- 14 Nov 2018 Status changed to active, no longer recruiting.
- 05 Jul 2018 Planned End Date changed from 1 Mar 2019 to 30 Nov 2018.
- 05 Jul 2018 Planned primary completion date changed from 20 Jul 2018 to 30 Nov 2018.